Published in Prog Clin Biol Res on January 01, 1988
Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest (2009) 1.78
[Leu31, Pro34]neuropeptide Y: a specific Y1 receptor agonist. Proc Natl Acad Sci U S A (1990) 1.50
Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest (1990) 1.44
Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. J Clin Invest (2007) 1.28
p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. Am J Pathol (2001) 1.10
Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res (2009) 1.09
IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Invest (2012) 1.07
Notch pathway activation induces neuroblastoma tumor cell growth arrest. Pediatr Blood Cancer (2011) 1.07
Isolation and structural analysis of a 1.2-megabase N-myc amplicon from a human neuroblastoma. Mol Cell Biol (1992) 0.95
Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. BMC Cancer (2010) 0.94
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood (2014) 0.90
The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma. Invest New Drugs (2010) 0.86
Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells. PLoS One (2012) 0.86
N-myc expression switched off and class I human leukocyte antigen expression switched on after somatic cell fusion of neuroblastoma cells. Mol Cell Biol (1990) 0.85
Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo. Cancer (2010) 0.85
The novel kinase inhibitor EMD1214063 is effective against neuroblastoma. Invest New Drugs (2014) 0.84
JARID1B Expression Plays a Critical Role in Chemoresistance and Stem Cell-Like Phenotype of Neuroblastoma Cells. PLoS One (2015) 0.80
Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines. Eur J Cancer (2010) 0.80
Etoposide sensitizes neuroblastoma cells expressing caspase 8 to TRAIL. Cell Biol Int Rep (2010) (2012) 0.80
PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma. J Cancer Ther Res (2013) 0.78
Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. BMC Cancer (2016) 0.76
Basic fibroblast growth factor enhances nerve growth factor receptor gene promoter activity in human neuroblastoma cell line CHP100. Mol Cell Biol (1992) 0.76
Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B. Genes Cancer (2016) 0.75
Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (1984) 9.64
Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med (1999) 9.02
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med (1985) 7.79
Random-clone strategy for genomic restriction mapping in yeast. Proc Natl Acad Sci U S A (1986) 6.44
Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res (1973) 4.65
The Ewing family of tumors--a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med (1994) 4.65
International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol (1988) 4.35
Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst (1989) 3.48
Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol (1999) 3.35
A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet (1994) 3.17
Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol (1991) 3.16
Synergistic interaction of macrophages and lymphocytes in antigen-induced transformation of lymphocytes. J Exp Med (1970) 3.08
Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol (2005) 2.97
Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J (1993) 2.91
Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc Natl Acad Sci U S A (1991) 2.77
McDonough feline sarcoma virus: characterization of the molecularly cloned provirus and its feline oncogene (v-fms). J Virol (1982) 2.76
Preferential amplification of the paternal allele of the N-myc gene in human neuroblastomas. Nat Genet (1993) 2.72
Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med (1993) 2.52
Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst (1999) 2.49
Effect of tumour necrosis factor on cultured human melanoma cells. Nature (1975) 2.46
Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci U S A (1989) 2.25
Chromosome translocation in peripheral neuroepithelioma. N Engl J Med (1984) 2.22
Cytogenetic features of human neuroblastomas and cell lines. Cancer Res (1981) 2.21
Comparison of Ewing's sarcoma of bone and peripheral neuroepithelioma. An immunocytochemical and ultrastructural analysis of two primitive neuroectodermal neoplasms. Arch Pathol Lab Med (1994) 2.18
International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer (2009) 2.13
High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer (1977) 2.07
Cytogenetic characterization of selected small round cell tumors of childhood. Cancer Genet Cytogenet (1986) 2.04
Malignant schwannoma--clinical characteristics, survival, and response to therapy. Cancer (1981) 2.04
Chromosomal aberrations in human neuroblastomas. Cancer (1977) 2.01
Extraskeletal Ewing's sarcoma: results of combined modality treatment. J Clin Oncol (1983) 1.99
Restriction endonuclease mapping of unintegrated proviral DNA of Snyder-Theilen feline sarcoma virus: localization of sarcoma-specific sequences. J Virol (1979) 1.98
Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. J Clin Oncol (1996) 1.94
Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer (1997) 1.94
Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol (1994) 1.92
Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst (1993) 1.88
Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol (1998) 1.88
High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res (2000) 1.85
Neuroblastoma and the differential diagnosis of small-, round-, blue-cell tumors. Hum Pathol (1983) 1.85
A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci U S A (1995) 1.82
Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene (1999) 1.79
Retinoblastoma--origin from a primitive neuroectodermal cell? Nature (1984) 1.78
Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol (2001) 1.76
Constitutional 1p36 deletion in a child with neuroblastoma. Am J Hum Genet (1993) 1.75
Dynamic model of differentiation in Ewing's sarcoma cells. Comparative analysis of morphologic, immunocytochemical, and oncogene expression parameters. Lab Invest (1992) 1.75
Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol (2000) 1.74
Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res (1995) 1.72
Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res (2001) 1.71
High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification. J Clin Invest (1991) 1.70
Absence of p53 gene mutations in primary neuroblastomas. Cancer Res (1993) 1.69
Experimental evidence for a neural origin of Ewing's sarcoma of bone. Am J Pathol (1987) 1.68
Morphology, growth, chromosomal pattern and fibrinolytic activity of two new human neuroblastoma cell lines. Cancer Res (1977) 1.66
A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer (1997) 1.63
Infrequent p53 gene mutations in medulloblastomas. Cancer Res (1991) 1.62
RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer, and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis. Cancer Res (1998) 1.62
Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol (2001) 1.58
Identification and characterization of the protein encoded by the human N-myc oncogene. Science (1986) 1.58
Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res (1990) 1.57
Lymphocyte-macrophage interaction in antigen induced in vitro lymphocyte transformation in patients with the Wiskott-Aldrich syndrome and other diseases with anergy. Cell Immunol (1972) 1.56
Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp Cell Res (1983) 1.53
The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene (2007) 1.53
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol (1987) 1.50
Aggressive surgery combined with intensive chemotherapy improves survival in poor-risk neuroblastoma. J Pediatr Surg (1991) 1.47
Residential pesticide exposure and neuroblastoma. Epidemiology (2001) 1.47
MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res (2001) 1.46
Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene (2007) 1.46
Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res (1998) 1.45
Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol (1997) 1.44
Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res (2001) 1.44
Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol (2000) 1.44
Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: a pediatric oncology group study. Neoplasia (2001) 1.44
Expression profiling of human tumors: the end of surgical pathology? J Mol Diagn (2001) 1.43
Intergroup Rhabdomyosarcoma Study: update for pathologists. Pediatr Dev Pathol (1999) 1.43
Consistent association of 1p loss of heterozygosity with pheochromocytomas from patients with multiple endocrine neoplasia type 2 syndromes. Cancer Res (1992) 1.43
Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol (1995) 1.42
Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med (1991) 1.42
Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol (2000) 1.42
Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res (1991) 1.41
Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol (2000) 1.40
Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene (1993) 1.38
Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol (1989) 1.36
An immunohistochemical study of pi class glutathione S-transferase expression in normal human tissue. Am J Pathol (1990) 1.35
Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proc Natl Acad Sci U S A (2000) 1.33
Sigma elements are position-specific for many different yeast tRNA genes. Nucleic Acids Res (1988) 1.32
Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res (1992) 1.31
Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res (1987) 1.31
Amplification units containing human N-myc and c-myc genes. Proc Natl Acad Sci U S A (1986) 1.31